Pharma Oligarch FTC Fix In?

https://news.yahoo.com/ftc-may-probe-pharmacy-benefit-100049…
The Federal Trade Commission will vote Thursday on whether it will study how pharmacy benefit managers affect drug prices and the businesses of pharmacies.

https://news.yahoo.com/ftc-wont-study-pharmacy-benefit-20291…
A motion on whether the Federal Trade Commission should study pharmacy benefit managers and how they’ve affected drug prices and pharmacy operations failed to get a majority vote today among FTC commissioners, who voted 2-2.

https://www.politico.com/news/2022/02/25/ftcs-top-economist-…
The Federal Trade Commission’s top economist abruptly quit last week amid internal disagreements over a proposed study into pharmacy benefit managers, three people familiar with the situation said.

Marta Wosinska, the FTC’s Bureau of Economics director, resigned on Feb. 16, a day before the FTC was set to vote on a study into PBMs, the companies that negotiate rebates from pharmaceutical manufacturers and develop lists of prescription drugs that health insurers will cover.

Wosinska — who specializes in health care economics and previously worked for the Food and Drug Administration — had served as the FTC’s top economist since April 2021.

5 Likes